metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Modificaciones pre y postoperatorias de las concentraciones plasmáticas de la P...
Journal Information
Vol. 72. Issue 4.
Pages 186-191 (October 2002)
Share
Share
Download PDF
More article options
Vol. 72. Issue 4.
Pages 186-191 (October 2002)
Full text access
Modificaciones pre y postoperatorias de las concentraciones plasmáticas de la PTH en la derivación biliopancreática de Larrad
Pre-and postoperative modifications of plasma parathyroid hormone concentrations in biliopancreatic diversion of Larrad
Visits
4644
Álvaro Larrad Jiméneza,1
Corresponding author
LARRAD@inicia.es

Correspondencia: Dr. A. Larrad Jiménez. Rafael Bergamín, 12, ático C, escalera izqda. 28043 Madrid.
, Fernando de la Fuente Simónb, Carlos Sánchez Cabezudoa, Irene Bretónc, Basilio Moreno Esteband
a Unidad de Cirugía Endocrinometabólica. Clínica Ruber. Madrid
b Departamento de Cirugía
c Secciones de Nutrición
d Obesidad. Hospital General Universitario Gregorio Marañón. Madrid
This item has received
Article information
Resumen
Objetivo

Estudiar las modificaciones de la partormona (PTH) y de la masa ósea tras derivación biliopancreática de Larrad.

Pacientes y métodos

Estudio restrospectivo del metabolismo del calcio, concentraciones de PTH y densitometría ósea en 100 pacientes obesos mórbidos consecutivos, 40 preoperatoriamente y 60 entre 1 y 5 años de la intervención, en los que se ha realizado un análisis de regresión logística de los posibles factores de riesgo.

Resultados

El 41,7% de los operados y el 25% de los no operados (p = 0,087) presentan elevaciones de la PTH. Las modificaciones son más frecuentes en mujeres (p = 0,000) y se normalizan de forma espontánea a partir de los 4 años de la intervención o con la adición de un suplemento oral de 2 g/día de calcio/vitamina D. Aparecen signos de osteopenia en el 17,5% de los operados y en el 13,3% de los no operados (p = 0,184). El único factor predictivo de aumento de PTH es la edad (riesgo relativo [RR]: 2,66). Para la osteopenia los factores predicitivos son la edad mayor de 40 años (RR: 18,53), la calciuria menor de 100 mg/24 h (RR: 4,04) y la fosfaturia mayor de 1.200 mg/24 h (RR: 3,86). La alteración secretora de PTH parece ser dependiente de un bajo aporte de calcio.

Conclusiones

La obesidad mórbida y la derivación biliopancreática originan un desequilibrio secretor de PTH secundario a un bajo aporte de calcio corregible con la adición de 2 g/día de calcio y/o vitamina D, y que produce una escasa repercusión sobre la masa ósea si es controlado.

Palabras clave:
Bypass biliopancreático
Hiperparatiroidismo secundario
Osteoporosis
Objective

To study modifications of parathyroid hormone (PTH) and bone mass after biliopancreatic diversion of Larrad.

Patients and methods

We performed a retrospective study of calcium metabolism, PTH concentrations and bone densitometry in 100 consecutive patients with morbid obesity. Preoperative modifications were studied in 40 patients and those occurring between 1 and 5 years after the operation were studied in 60 patients. Logistic regression analysis was used to evaluate possible risk factors.

Results

Elevated PTH concentrations were found in 41.7% of the postoperative group and in 25% of the preoperative group (p 0.087). Modifications were more frequent in women (p 0.000) and returned to normal spontaneously 4 years after the intervention or with oral supplementation with 2g/day of calcium/vitamin D. Signs of osteopenia were found in 17.5% of the postoperative group and in 13.3% of the preoperative group (p 0.184). The only predictive factor for increased PTH levels was age (RR: 2.66). Predictive factors for osteopenia were age older than 40 years (RR: 18.53), calciuria lower than 100 mg/24h (RR: 4.04) and phosphaturia higher than 1200 mg/24h (RR: 3.86). Alterations in PTH secretion seemed to be due to low calcium intake.

Conclusions

Morbid obesity and biliopancreatic diversion create an imbalance in PTH secretion secondary to low calcium intake, which can be corrected by supplementation with 2 g/day of calcium and/or vitamin D and which has few effects on bone mass if controlled.

Key words:
Biliopancreatic bypass
Secondary hyperparathyroidism
Osteoporosis
Full text is only aviable in PDF
Bibliografía
[1.]
N. Scopinaro, E. Gianetta, D. Civalleri, U. Bonalumi, V. Bachi.
Biliopancreatic bypass for obesity: II. Initial experience in man.
Br J Surg, 66 (1979), pp. 619-620
[2.]
N. Scopinaro, E. Gianetta, D. Civalleri, O. Bonalumi, V. Bachi.
Two years of clinical experience with bilio-pancreatic bypass for obesity.
Am J Clin Nutr, 33 (1980), pp. 506-514
[3.]
N. Scopinaro, E. Gianetta, D. Friedman, G. Adami, E. Traverso, V. Bachi.
Evolution of biliopancreatic bypass.
Clin Nutr, 5 (1986), pp. 137-146
[4.]
J.E. Compston, S. Vedi, E. Gianetta, G. Watson, D. Civalleri, N. Scopinaro.
Bone histomorphometry and vitamin D status after biliopancreatic bypass for obesity.
Gastroentrology, 87 (1984), pp. 350-356
[5.]
D.K. Hoolian, M.W. Clare.
Biliopancreatic bypass for morbid obesity: Late results and complications.
Clin Nutr, 5 (1986), pp. 133-136
[6.]
B.L. Chapin, H.J. LeMar, D.H. Knodel, P.L. Carter.
Secondary hyperparathyroidism following biliopancreatic diversion.
Arch Surg, 113 (1996), pp. 1048-1052
[7.]
A. Larrad, C. Sánchez-Cabezudo, B. Moreno, I. Breton.
Estudio comparativo entre la gastroplastia vertical anillada y la derivación biliopancreática en el tratamiento de la obesidad mórbida.
Cir Esp, 66 (1999), pp. 297-302
[8.]
J.H. Sellin, S.C. Meredith, S. Kelly, H. Schneir, I.H. Rosenberg.
Prospective evaluation of metabolic bone disease after jejunoileal bypass.
Gastroenterology, 87 (1984), pp. 123-129
[9.]
A.M. Parfitt, J. Podenphant, A.R. Villanueva, B. Frame.
Metabolic bone disease with and without osteomalacia after intestinal bypass surgery: A bone histomorphometric study.
Bone, 6 (1985), pp. 211-220
[10.]
T. Cundy, M.C. Evans, R.G. Kay, M. Dowman, D. Mattie, I.R. Reid.
Effects of vertical-banded gastroplasty on bone and mineral metabolism in obese patients.
Br J Surg, 83 (1996), pp. 1468-1472
[11.]
V.V. Gossain, D.S. Rao, M.J. Carella, G. Divine, D.R. Rovner.
Bone mineral density (BMD) in obesity. Effect of weight loss.
J Med, 30 (1999), pp. 367-376
[12.]
S. Prieto.
Control del metabolismo del calcio, fósforo y magnesio. En.
Fisiología humana. 2.ª ed, pp. 979-993
[13.]
N. Scopinaro, G.F. Adami, G.M. Marinari, E. Gianetta, E. Traverso, D. Friedman, et al.
Biliopancreatic diversion.
World J Surg, 22 (1998), pp. 936-946
[14.]
C. Sánchez-Cabezudo, A. Larrad.
Gastrointestinal side-effects after biliopancreatic diversion of Larrad: evolution on long-term.
Obes Surg, 10 (2000), pp. 350
[15.]
J.C. Bai, E.C. Mauriño.
Enfermedad metabólica ósea asociada a la enfermedad celíaca.
Gastroenterol Hepatol, 20 (1997), pp. 209-216
[16.]
F.R. Bringhurst, M.B. Demay, H.M. Kronenberg.
Hormones and disorders of mineral metabolism. En.
Williams text book of endocrinology. 9.ª ed, pp. 1155-1209
[17.]
T. Andersen, P. Mcnair, N. Fogh-Andersen, I. Transbol.
Calcium homeostasis in morbid obesity.
Miner Electrolyte Metab, 10 (1984), pp. 316-318
[18.]
T. Andersen, P. McNair, N. Fogh-Andersen, T.T. Nielsen, L. Hyldstrup, I. Transbol.
Increased parathyroid hormone as a consequence of changed complex binding of plasma calcium in morbid obesity.
Metabolism, 35 (1986), pp. 147-151
[19.]
T. Andersen, P. McNair, L. Hyldstrup, N. Fogh-Andersen, T.T. Nielsen, A. Astrup, I. Transbol.
Secondary hyperparathyroidism of morbid obesity regresses during weight reduction.
Metabolism, 37 (1988), pp. 425-428
[20.]
Y. Nishizawa, H. Koyama, T. Shoji, H. Tahara, S. Hagiwara, H. Aratani, et al.
altered calcium homeostasis accompanying of regional bone mineral during a vey-low-caloric diet.
Am J Clin Nutr, 56 (1992), pp. S265-267
[21.]
A. Rodríguez García, C. Díaz-Miguel Pérez, M. Vázquez Díaz, G. Martín Peña, J. Beltrán Gutiérrez.
Medición ultrasónica del hueso en mujeres sanas y factores relacionados con la masa ósea.
Med Clin (Barc, 113 (1998), pp. 285-289
[22.]
F. Durante, S. Buffa, E. Putignano, G. Scuderi, M. Sparacino, G. Ferrantelli, et al.
Caloric intake and bone mineral content in obese and normal weight subjets.
Minerva Endocrinol, 15 (1990), pp. 181-184
[23.]
N. Tolosa de Talamoni, V. Centeno.
Low calcium diets in humans: classic models to understand calcium homeostasis and vitamin D endocrine system.
Endocrinologia, 46 (1999), pp. 241-244
[24.]
P. Aguado, M.V. Garcés, M.L. Gozález Casaús, M.T. Del Campo, P. Richi, J. Coya, et al.
Alta prevalencia de deficiencia de vitamina D en mujeres posmenopáusicas de una consulta reumatológica en Madrid. Evaluación de dos pautas de prescripción de vitamina D.
Med Clin (Barc, 114 (2000), pp. 326-330
[25.]
N.H. Bell, S. Epstein, A. Green, J. Shary, M.J. Oexmann, S. Shaw.
Evidence for alteration of the vitamin D-endocrine system in obese subjets.
J Clin Invest, 76 (1985), pp. 370-373
[26.]
J. Kerstetter, B. Caballero, K. O’Brien, R. Wurtman, L. Allen.
Mineral homeostasis in obesity: effects of euglycemic hyperinsulinism.
Matabolism, 40 (1991), pp. 707-713
[27.]
G. Rumenapf, J. Schmidtler, P.O. Schwille.
Intestinal calcium absortion during hyperinsulinemic euglycemic glucosa clamp in healthy humans.
Calcific Tissue Int, 46 (1990), pp. 73-79
[28.]
J.E. Kerstetter, D.M. Caseria, M.E. Mitnick, A.F. Ellison, L.F. Gay, T.A. Liskov, et al.
Increased circulating concentrations of parathyroid hormone in healthy, young women consuming a protein-restricted diet.
Am J Clin Nutr, 66 (1997), pp. 1188-1196
[29.]
J.E. Kerstetter, C.M. Svastisalee, D.M. Caseria, M.E. Mitnick, K.L. Insogna.
A threshold for low-protein-diet-induced elevations in patathyroid hormone.
Am J Clin Nutr, 72 (2000), pp. 168-173
[30.]
L. Lind, H. Lithell, A. Hvarfner, T. Pollare, S. Ljunghall.
On the relationships between mineral metabolism, obesity and fat distribution.
Eur J Clin Invest, 23 (1993), pp. 307-310
[31.]
J. Sundgot-Borgen, R. Bahr, J.A. Falch, L. Sundgot-Schneider.
Normal bone mass in bulimic women.
J Clin Endocrinol Metab, 83 (1998), pp. 3144-3149
[32.]
L.V. Crowley, J. Seay, G. Mullin.
Late effects of gastric bypass for obesity.
Am J Gastroenterol, 79 (1984), pp. 850-860
[33.]
E.D. Mason.
Bone disease fron duodenal exclusion.
Obesity Surgery, 10 (2000), pp. 585-586
[34.]
H. Rico Lenza.
Alteraciones gastrointestinales que se complican con enfermedades oseo-metabólicas. En.
El síndrome osteoporótico, pp. 95-98
[35.]
V. Luna López, M.L. Fernández Soto, F. Escobar Jiménez.
Nutrición y osteoporosis: una relación consolidada.
Med Clin (Barc), 109 (1997), pp. 271-275
Copyright © 2002. Asociación Española de Cirujanos
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos